Skip to main content

A Phase 1, Open-Label, Multicenter, Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD70 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX130) in Adult Subjects With Relapsed or Refractory T or B Cell Malignancies

Clinical Trial Grant
Duke Scholars

Administered By

Duke Cancer Institute

Awarded By

CRISPR Therapeutics

Start Date

March 1, 2022

End Date

June 30, 2027
 

Administered By

Duke Cancer Institute

Awarded By

CRISPR Therapeutics

Start Date

March 1, 2022

End Date

June 30, 2027